Startups 2018

Pantherna Therapeutics GmbH

Dr Klaus Giese, Dr Jörg Kaufmann, Dr Oliver Keil, Dr Gerrit Maass

Innovation & Business Idea

Pantherna Therapeutics is a biopharmaceutical company developing first-in-class therapeutics for vascular diseases by restoring endothelial cell function.


Customers / Target Market

Biotech & Big Pharma


Competitors

Biotech & Big Pharma (Nucleic acid based Therapeutics)


Intellectual Property Status

Patent applications in preparation


Development Status & Future Steps

Research & Preclinical


Exit Strategy

Trade sale & IPO


Team Description

Dr. Klaus Giese, CEO. Former CEO/CSO, Erdmann Technologies, Berlin; CSO, Silence Therapeutics, London/Berlin; Senior Scientist, Chiron Corporation, Emeryville; Scientist, HHMI, Univ. of California, San Francisco (UCSF); PhD Biochemistry, Berlin. Dr. Jörg Kaufmann, CSO. Former CSO, Silence Therapeutics, London/Berlin; Senior Scientist, Chiron Corporation, Emeryville; Group Leader Institute of Tumor Biology (IMT), Marburg; Postdoctoral Fellow, HHMI, Univ. of California, Los Angeles (UCLA), PhD Molecular Genetics, Marburg. Dr. Oliver Keil, COO. Former Head of CMC, Silence Therapeutics, London/Berlin; Head of Chemistry & Formulation, G.O.T. Therapeutics, Berlin; Postdoctoral Fellow/ Group leader Non-viral Gene Transfer, University of Düsseldorf, PhD Chemistry, Wuppertal. Dr. Gerrit Maass, CFO. Former CEO/CFO Erdmann Technologies, Berlin; General Counsel at MetrioPharm GmbH, Berlin; Accredited and fully qualified lawyer; PhD in Political Sciences, TU Braunschweig; BSc in plant biotechnology, Hannover.


Financing Need

€2-3 M


Searching for

Commercial Partner, Funding, Collaboration

 

Pantherna Therapeutics GmbH